A ropy exopolysaccharide producing strain Bifidobacterium longum subsp. longum YS108R alleviates DSS-induced colitis by maintenance of the mucosal barrier and gut microbiota modulation.
A ropy exopolysaccharide producing strain Bifidobacterium longum subsp. longum YS108R alleviates DSS-induced colitis by maintenance of the mucosal barrier and gut microbiota modulation.
复制标题
DOI：
10.1039/c9fo00014c
复制
发表时间：
2019-03
期刊：
影响因子：
6.1
通讯作者：
Shuang Yan;Bo Yang;Jichun Zhao;Jianxin Zhao;C. Stanton;R. P. Ross;Hao Zhang;Wei Chen
中科院分区：
文献类型：
--
作者：
Shuang Yan;Bo Yang;Jichun Zhao;Jianxin Zhao;C. Stanton;R. P. Ross;Hao Zhang;Wei Chen
据报道，长杆菌对结肠炎有缓解作用，但结果也表明不同菌株之间存在显著差异。在本研究中，我们比较了长杆菌亚种的作用。不同性质的Long um菌株产生EPS对DSS诱导的结肠炎的影响。研究一株胞外多糖(EPS)产生菌--长双歧杆菌的缓解作用。将6-8周龄雄性C57BL/6J小鼠随机分为6组(n=8)：正常对照组、DSS结肠炎模型组和DSS结肠炎模型组。Long um菌株(YS108R、C11A10B和HAN4-25)和动物芽孢杆菌亚种。乳酸菌BB12，其中YS108R产生粘性EPS，C11A10B产生非粘性EPS，HAN4-25不产生EPS，BB12为阳性对照。ROPY-EPS产生菌YS108R能减轻DSS诱导的小鼠的症状和炎症反应，其中YS108R能降低DSS攻击后的促炎细胞因子IL-6和IL-17A的水平(分别从102±45.22和22.14±5.43降至37.95±20.33pg·L~(-1)和12.58±2.74，p<0.05)，而另一株非ROPY-EPS产生菌C11A10B不能降低上述促炎细胞因子的水平。此外，YS108R能够维持粘膜屏障相关基因的表达水平，而非EPS产生菌HAN4-25在DSS攻击后不能维持这些基因的表达水平。肠道微生物区系分析表明，DSS处理显著提高了肠杆菌科和消化链球菌科的相对丰度(0.2623±0.162和0.0512±0.0361)，降低了S24-7的相对丰度(0.042±0.0326)，而YS108R可使肠杆菌科和消化链球菌的相对丰度分别降低到0.0848±0.0399和0.0032±0.0047，使S24-7的相对丰度增加到0.2625±0.0566(p<；0.05)。结果表明，长杆菌亚种具有较强的致病力。Long um YS108R通过调节炎症相关细胞因子，维持正常粘膜屏障，逆转微生物区系变化，减轻DSS诱导的结肠炎。
B. longum has been reported to exert an alleviative effect on colitis, but the results also suggested significant differences among strains. Here in this study, we compared the effect of B. longum subsp. longum strains with different properties in EPS production on DSS-induced colitis. To investigate the alleviative effect of a ropy-exopolysaccharide (EPS) producing strain, Bifidobacterium longum subsp. longum YS108R, on experimental colitis, C57BL/6J mice (male, 6-8 weeks old) were randomly assigned to six groups (n = 8): normal control, DSS colitis and four DSS colitis groups orally administered with three B. longum subsp. longum strains (YS108R, C11A10B and HAN4-25) and B. animalis subsp. lactis BB12, respectively, in which YS108R produced ropy-EPS, C11A10B produced non-ropy-EPS, HAN4-25 did not produce EPS and BB12 was set as a positive control. Ropy-EPS producing strain YS108R could alleviate the symptoms and remit inflammation induced by DSS, in which YS108R could decrease the pro-inflammatory cytokine IL-6 and IL-17A levels after DSS challenge (from 102 ± 45.22 to 37.95 ± 20.33 pg mL-1 and from 22.14 ± 5.43 to 12.58 ± 2.74, p < 0.05), but another non-ropy-EPS producing strain C11A10B did not decrease the levels of these pro-inflammatory cytokines. Furthermore, YS108R could maintain the expression levels of genes related to the mucosal barrier, but strain HAN4-25, a non-EPS producer, was not able to maintain the expression levels of these genes after DSS challenge. Analysis of gut microbiota showed that DSS treatment significantly increased the relative abundance of Enterobacteriaceae and Peptostreptococcaceae (0.2623 ± 0.162 and 0.0512 ± 0.0361) and decreased the relative abundance of S24-7 (0.042 ± 0.0326); however, YS108R administration could decrease the relative abundance of Enterobacteriaceae and Peptostreptococcaceae to 0.0848 ± 0.0399 and 0.0032 ± 0.0047 and increase the relative abundance of S24-7 to 0.2625 ± 0.0566 (p < 0.05). The results showed that B. longum subsp. longum YS108R could alleviate DSS-induced colitis by modulating the inflammation related cytokines, maintenance of the normal mucosal barrier and reverting the change of microbiota.